Search Result

Results for "

β-catenin peptide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	β-catenin (13) E1/E2/E3 Enzyme (1) GSK-3 (2) Molecular Glues (2) Wnt (11)
By Research Areas:	Cancer (18)

Inhibitors & Agonists

Peptides

Targets Recommended: β-catenin Formyl Peptide Receptor (FPR) Connective Peptide Peptide-Drug Conjugates (PDCs) Natriuretic Peptide Receptor (NPR) RXFP Receptor CGRP Receptor Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P4858

C-Peptide 1 (rat)	GSK-3 Wnt	Cancer
C-Peptide 1 (rat), a peptide, is aβ-catenin/GSK-3β activator. C-Peptide 1 (rat) can regulate the Wnt/β-catenin signaling pathway. C-Peptide 1 (rat) can be used for the research of cancer .

HY-111836

NRX-252114	Molecular Glues β-catenin	Cancer
NRX-252114 is a potent enhancer of the interaction between *β-catenin, and its cognate E3 ligase, SCF ^β-TrCP. NRX-252114 enhances the binding of pSer33/S37A β-catenin* peptide for β-TrCP with an EC₅₀ of 6.5 nM and a K_d of 0.4 nM. NRX-252114 induces mutant β-catenin degradation .

HY-141448

NRX-2663	β-catenin E1/E2/E3 Enzyme	Cancer
NRX-2663 is an enhancer of the interaction between *β-catenin, and its cognate E3 ligase, SCF ^β-TrCP. NRX-2663 enhances the binding of β-catenin* peptide for β-TrCP with an EC₅₀ of 22.9 μM and a K_d of 54.8 nM .

HY-141450

NRX-103095	β-catenin	Cancer
NRX-103095 is an enhancer of the interaction between *β-catenin, and its cognate E3 ligase, SCF ^β-TrCP. NRX-103095 enhances the binding of pSer33/Ser37 β-catenin* peptide for β-TrCP with an EC₅₀ of 163 nM .

HY-141449

NRX-103094	Molecular Glues β-catenin	Cancer
NRX-103094 is a potent enhancer of the interaction between *β-catenin, and its cognate E3 ligase, SCF ^β-TrCP. NRX-103094 enhances the binding of pSer33/Ser37 β-catenin* peptide for β-TrCP with an EC₅₀ of 62 nM and a K_d of 0.6 nM .

HY-P10392B

aStAx-35R TFA	β-catenin Wnt	Cancer
aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of *β-catenin* and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells .

HY-P1589

**β-catenin peptide**	β-catenin	Cancer
β-catenin peptide is a 8-aa peptide, and can promote thymocyte positive selection.

HY-P10392

aStAx-35R	β-catenin Wnt	Cancer
aStAx-35R, a stapled peptide, antagonizes nuclear form of *β-catenin* and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells .

HY-124826

BC21 NSC 109268	β-catenin	Cancer
BC21 (NSC 109268) is a *β-catenin/Tcf4* inhibitor with an IC₅₀ of 5 μM. BC21 effectively inhibits the binding of β-catenin to Tcf4-derived peptides and suppresses β-catenin/Tcf4-driven reporter gene activity. BC21 can be utilized in cancer research .

HY-107528

FRATtide	β-catenin GSK-3	Cancer
FRATtide is a peptide derived from the GSK-3 binding protein that inhibits the phosphorylation of Axin and *β-catenin. FRATtide inhibits GSK-3* binding to Axin .

HY-P1416

Foxy-5 Maximum Cited Publications 6 Publications Verification	Wnt	Cancer
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-P1416A

Foxy-5 TFA Maximum Cited Publications 6 Publications Verification	Wnt	Cancer
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-P10392AF

fStAx-35R TFA	Wnt β-catenin	Cancer
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits *Wnt/β-catenin* signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .

HY-P2272

NLS-StAx-h	Wnt β-catenin	Cancer
NLS-StAx-h is a selective, cell permeable, stapled peptide Wnt signaling inhibitor with an IC₅₀ of 1.4 μM. NLS-StAx-h efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h shows anti-proliferation of cancer cells .

HY-P2272A

NLS-StAx-h TFA 1 Publications Verification	Wnt β-catenin	Cancer
NLS-StAx-h TFA is a selective, cell permeable, stapled peptide Wnt signaling inhibitor with an IC₅₀ of 1.4 μM. NLS-StAx-h TFA efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h TFA shows anti-proliferation of cancer cells .

HY-P10810

QPH-FR	Wnt β-catenin	Cancer
QPH-FR, a quinoa peptide, is a leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) inhibitor. QPH-FR competitively suppresses the formation of the LGR5/RSPO1 complex by binding to LGR5. QPH-FR causes RNF43/ZNRF3 to ubiquitinate the FZD receptor, thereby suppressing the *Wnt/β-catenin* signaling pathway and exerting stemness inhibition .

HY-P1454

Fz7-21 3 Publications Verification Ac-LPSDDLEFWCHVMY-NH2	Wnt	Cancer
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC₅₀ values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs the function of FZD7 in Wnt–β-catenin signalling and stem cell function in intestinal organoids .

HY-P1454A

Fz7-21 TFA 3 Publications Verification Ac-LPSDDLEFWCHVMY-NH2 TFA	Wnt	Cancer
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC₅₀ values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids .

Cat. No.	Product Name	Target	Research Area

HY-P4858

C-Peptide 1 (rat)	GSK-3 Wnt	Cancer
C-Peptide 1 (rat), a peptide, is aβ-catenin/GSK-3β activator. C-Peptide 1 (rat) can regulate the Wnt/β-catenin signaling pathway. C-Peptide 1 (rat) can be used for the research of cancer .

HY-P10392B

aStAx-35R TFA	β-catenin Wnt	Cancer
aStAx-35R TFA, a stapled peptide, antagonizes nuclear form of *β-catenin* and inhibits Wnt signaling. aStAx-35R TFA inhibits competitively the binding of β-catenin to TCF4. aStAx-35R TFA selectively induces growth inhibition of Wnt-dependent cancer cells .

HY-P1416

Foxy-5 Maximum Cited Publications 6 Publications Verification	Wnt	Cancer
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-P1416A

Foxy-5 TFA Maximum Cited Publications 6 Publications Verification	Wnt	Cancer
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-P10392AF

fStAx-35R TFA	Wnt β-catenin	Cancer
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits *Wnt/β-catenin* signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .

HY-P2272A

NLS-StAx-h TFA 1 Publications Verification	Wnt β-catenin	Cancer
NLS-StAx-h TFA is a selective, cell permeable, stapled peptide Wnt signaling inhibitor with an IC₅₀ of 1.4 μM. NLS-StAx-h TFA efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h TFA shows anti-proliferation of cancer cells .

HY-P1589

**β-catenin peptide**	β-catenin	Cancer
β-catenin peptide is a 8-aa peptide, and can promote thymocyte positive selection.

HY-P10392

aStAx-35R	β-catenin Wnt	Cancer
aStAx-35R, a stapled peptide, antagonizes nuclear form of *β-catenin* and inhibits Wnt signaling. aStAx-35R inhibits competitively the binding of β-catenin to TCF4. aStAx-35R selectively induces growth inhibition of Wnt-dependent cancer cells .

HY-107528

FRATtide	β-catenin GSK-3	Cancer
FRATtide is a peptide derived from the GSK-3 binding protein that inhibits the phosphorylation of Axin and *β-catenin. FRATtide inhibits GSK-3* binding to Axin .

HY-P2272

NLS-StAx-h	Wnt β-catenin	Cancer
NLS-StAx-h is a selective, cell permeable, stapled peptide Wnt signaling inhibitor with an IC₅₀ of 1.4 μM. NLS-StAx-h efficiently inhibits β-catenin-transcription factor interactions. NLS-StAx-h shows anti-proliferation of cancer cells .

HY-P10810

QPH-FR	Wnt β-catenin	Cancer
QPH-FR, a quinoa peptide, is a leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) inhibitor. QPH-FR competitively suppresses the formation of the LGR5/RSPO1 complex by binding to LGR5. QPH-FR causes RNF43/ZNRF3 to ubiquitinate the FZD receptor, thereby suppressing the *Wnt/β-catenin* signaling pathway and exerting stemness inhibition .

HY-P1454

Fz7-21 3 Publications Verification Ac-LPSDDLEFWCHVMY-NH2	Wnt	Cancer
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC₅₀ values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs the function of FZD7 in Wnt–β-catenin signalling and stem cell function in intestinal organoids .

HY-P1454A

Fz7-21 TFA 3 Publications Verification Ac-LPSDDLEFWCHVMY-NH2 TFA	Wnt	Cancer
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC₅₀ values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.